URT
H1 2026 report
Net income
-46 k PLN
— YoY
EBITDA
197 k PLN
— YoY
FCF
-11.19 m PLN
— YoY
CFO
-4.14 m PLN
— YoY
Summary
Investment thesis
- Zysk operacyjny 50 tys. zł w 1H2026 (wobec straty 2 510 tys. zł rok wcześniej) jest w całości efektem odwrócenia kosztów programu motywacyjnego (+3 799 tys. zł) – bez tego strata operacyjna wynosiłaby ok. 3,7 mln zł.
- Gotówka spadła z 8,8 mln do 1,3 mln zł w pół roku; przepływy operacyjne -4,1 mln zł, a nakłady na prace rozwojowe 6,9 mln zł.
- Audytor zwrócił uwagę na założenie kontynuacji działalności – zarząd przyznaje, że potrzebne jest dodatkowe finansowanie (emisje akcji 5,5 mln zł w IV kw. 2026 i 5,0 mln zł w II kw. 2027).
- Katalizatory: refundacja ok. 7,3 mln zł z dotacji, patent USPTO dla markera raka trzustki (PANURI), postęp projektów dofinansowanych z NCBR/PARP.
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
URT · H1 2026
| Metric | H1 2026 | H1 2025 | Δ YoY | YTD 2026 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|---|---|
| EBITDA | 197 | — | — | 197 | — | derived | — | 0.70 |
| EBIT | 50 | — | — | 50 | — | reported | — | 1.00 |
| EBT | -33 | — | — | -33 | — | reported | — | 1.00 |
| Net income | -46 | — | — | -46 | — | reported | — | 1.00 |
| EPS (basic) (PLN) | -0.03 | — | — | -0.03 | — | reported | — | 1.00 |
| EPS (diluted) (PLN) | -0.03 | — | — | -0.03 | — | reported | — | 1.00 |
| D&A | 147 | — | — | 147 | — | reported | — | 1.00 |
| Shares (basic) (units) | 1,526,080 | — | — | 1,526,080 | — | reported | — | 1.00 |
| Cash | 1,330 | — | — | — | — | reported | — | 1.00 |
| Total debt | 742 | — | — | — | — | reported | — | 0.85 |
| Net debt | -588 | — | — | — | — | derived | — | 0.70 |
| Equity | 22,525 | — | — | — | — | reported | — | 1.00 |
| Total assets | 40,759 | — | — | — | — | reported | — | 1.00 |
| Working capital | 4,962 | — | — | — | — | derived | — | 0.70 |
| Current assets | 9,267 | — | — | — | — | reported | — | 1.00 |
| Current liabilities | 4,305 | — | — | — | — | reported | — | 1.00 |
| Non-current liabilities | 13,929 | — | — | — | — | reported | — | 1.00 |
| Trade receivables | 7,937 | — | — | — | — | reported | — | 0.80 |
| Trade payables | 2,849 | — | — | — | — | reported | — | 0.80 |
| Goodwill | 29,335 | — | — | — | — | reported | — | 1.00 |
| Tangible equity | -6,810 | — | — | — | — | derived | — | 0.70 |
| CFO | -4,141 | — | — | -4,141 | — | reported | — | 1.00 |
| CapEx | 7,050 | — | — | 7,050 | — | reported | — | 0.90 |
| FCF | -11,191 | — | — | -11,191 | — | derived | — | 0.70 |
| Current ratio | 2.15x | — | — | — | — | derived | — | 0.70 |
| Quick ratio | 2.15x | — | — | — | — | derived | — | 0.70 |
| Cash ratio | 0.31x | — | — | — | — | derived | — | 0.70 |
| Debt / equity | 0.03x | — | — | — | — | derived | — | 0.70 |
| Debt / assets | 0.02x | — | — | — | — | derived | — | 0.70 |
| Net debt / equity | -0.03x | — | — | — | — | derived | — | 0.70 |
H1 2026 · Δ YoY
EBITDA
197
—
197
—
- H1 2025
- —
- YTD 2026
- 197
- Δ YoY
- —
EBIT
50
—
50
—
- H1 2025
- —
- YTD 2026
- 50
- Δ YoY
- —
EBT
-33
—
-33
—
- H1 2025
- —
- YTD 2026
- -33
- Δ YoY
- —
Net income
-46
—
-46
—
- H1 2025
- —
- YTD 2026
- -46
- Δ YoY
- —
EPS (basic)
(PLN)
-0.03
—
-0.03
—
- H1 2025
- —
- YTD 2026
- -0.03
- Δ YoY
- —
EPS (diluted)
(PLN)
-0.03
—
-0.03
—
- H1 2025
- —
- YTD 2026
- -0.03
- Δ YoY
- —
D&A
147
—
147
—
- H1 2025
- —
- YTD 2026
- 147
- Δ YoY
- —
Shares (basic)
(units)
1,526,080
—
1,526,080
—
- H1 2025
- —
- YTD 2026
- 1,526,080
- Δ YoY
- —
Cash
1,330
—
1,330
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total debt
742
—
742
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt
-588
—
-588
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Equity
22,525
—
22,525
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total assets
40,759
—
40,759
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Working capital
4,962
—
4,962
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current assets
9,267
—
9,267
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current liabilities
4,305
—
4,305
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Non-current liabilities
13,929
—
13,929
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Trade receivables
7,937
—
7,937
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Trade payables
2,849
—
2,849
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Goodwill
29,335
—
29,335
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Tangible equity
-6,810
—
-6,810
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
CFO
-4,141
—
-4,141
—
- H1 2025
- —
- YTD 2026
- -4,141
- Δ YoY
- —
CapEx
7,050
—
7,050
—
- H1 2025
- —
- YTD 2026
- 7,050
- Δ YoY
- —
FCF
-11,191
—
-11,191
—
- H1 2025
- —
- YTD 2026
- -11,191
- Δ YoY
- —
Current ratio
2.15x
—
2.15x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Quick ratio
2.15x
—
2.15x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Cash ratio
0.31x
—
0.31x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Debt / equity
0.03x
—
0.03x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Debt / assets
0.02x
—
0.02x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt / equity
-0.03x
—
-0.03x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —